NCT04766736

Netrin-1 & Hepatocellular Carcinoma HCC

Netrin-1 in Hepatocellular Carcinoma: Pathology, Preclinical Targeting, and Definition of Eligibility Criteria for Phase 1 Trials

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 320 (estimated)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Netrin-1 is a dependence receptor ligand participating in the pathology of several cancer types. It is up-regulated in chronic liver diseases, cirrhosis and HCC. We hypothesize that netrin-1 may play a detrimental role in HCC. The goal of this project is to characterize netrin-1 signals in HCC samples with ad hoc controls, to investigate the benefit of capturing netrin-1 in preclinical models of HCC and to try to define patients groups the most likely to benefit from this targeting approach in the clinic.

Conditions

• HCC

Interventions

Type	Name	Description
PROCEDURE	Quantification of netrin-1 signals by antibody-based approaches	Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.

Timeline

• Start date: 2019-07-01
• Primary completion: 2021-06-30
• Completion: 2022-12-31
• First posted: 2021-02-23
• Last updated: 2021-02-23

Locations

1 site across 1 country: France